Pharmazentrum Frankfurt/ZAFES, Goethe University Hospital, Frankfurt am Main, Germany.
Front Immunol. 2018 Feb 16;9:163. doi: 10.3389/fimmu.2018.00163. eCollection 2018.
Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are serious autoimmune liver diseases that are characterized by a progressive destruction of the liver parenchyma and/or the hepatic bile ducts and the development of chronic fibrosis. Left untreated autoimmune liver diseases are often life-threatening, and patients require a liver transplantation to survive. Thus, an early and reliable diagnosis is paramount for the initiation of a proper therapy with immunosuppressive and/or anticholelithic drugs. Besides the analysis of liver biopsies and serum markers indicating liver damage, the screening for specific autoantibodies is an indispensable tool for the diagnosis of autoimmune liver diseases. Such liver autoantigen-specific antibodies might be involved in the disease pathogenesis, and their epitope specificity may give some insight into the etiology of the disease. Here, we will mainly focus on the generation and specificity of autoantibodies in AIH patients. In addition, we will review data from animal models that aim toward a better understanding of the origins and pathogenicity of such autoantibodies.
自身免疫性肝炎(AIH)、原发性胆汁性胆管炎(PBC)和原发性硬化性胆管炎(PSC)是严重的自身免疫性肝病,其特征为肝实质和/或肝内胆管进行性破坏以及慢性纤维化的发展。如果不加以治疗,自身免疫性肝病往往会危及生命,患者需要进行肝移植才能存活。因此,早期和可靠的诊断对于启动适当的免疫抑制和/或利胆药物治疗至关重要。除了分析提示肝损伤的肝活检和血清标志物外,筛查特定的自身抗体也是诊断自身免疫性肝病不可或缺的工具。这些肝自身抗原特异性抗体可能参与疾病的发病机制,其表位特异性可能为疾病的病因提供一些见解。在这里,我们将主要关注 AIH 患者自身抗体的产生和特异性。此外,我们还将回顾动物模型的数据,以更好地了解这些自身抗体的起源和致病性。